Delcath Systems (DCTH) Soars 5.85% on Revenue Growth, U.S. Expansion

Delcath Systems (DCTH) surged 5.85% today, marking its fifth consecutive day of gains and a 25.26% increase over the past five days. The share price reached its highest level since March 2021, with an intraday decline of NaN%.

The strategy of buying DCTH shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 7.5% annualized gain. However, the overall performance was slightly underwhelming, with a 5-year total return of 37.5%, compared to the SPY ETF's return of 57.5% over the same period. This suggests that while the strategy provided some growth, it may not have been the most optimal approach for maximizing returns in the context of DCTH's performance.

Delcath Systems has recently achieved a significant milestone by reaching a 52-week high of $17.17. This surge is attributed to the company's strong revenue growth, improved profitability, and successful U.S. expansion following the post-HEPZATO launch. These developments have marked a pivotal point for the biotech company, driving investor confidence and contributing to the recent stock price increase.